TNM / FIGO – radioterapie.eu

Testing build. Deterministic source-linked rules are implemented, but this package is not yet approved for independent patient-care decisions. No case data are stored.

Cancer / systemMore tumour systems will plug into the same CSCE engine after validation.

1 · Pathology & uterine extent

HistologyDefines non-aggressive vs aggressive FIGO grouping. Endometrioid gradeRequired for endometrioid histology. Myometrial invasion (%)0, <50%, or ≥50% are stage-defining boundaries. LVSI involved vessels0 none · 1–4 focal · ≥5 substantial. Confined to polyp/endometriumRelevant when myometrial invasion is absent. Cervical stromal invasionGlandular extension alone is not the same criterion.

2 · Adnexa, serosa, vagina & peritoneum

Ovarian involvementFallopian tube involvementUterine subserosa involvementUterine serosa involvementVaginal involvementParametrial involvementPelvic peritoneal involvement

If ovarian involvement is present, IA3 requires all favourable criteria below

Ovarian histology low-grade endometrioidUnilateral ovarian diseaseConfined to ovaryOvarian capsule breach/rupture

3 · Nodes & distant disease

Pelvic node metastasisLargest pelvic nodal deposit (mm)Pelvic tumour-cell count Para-aortic node metastasisLargest para-aortic deposit (mm)Para-aortic tumour-cell count Bladder mucosal invasionBowel mucosal invasionExtrapelvic peritoneal metastasisDistant metastasisMetastatic nodes above renal vessels

Corrigendum-aware nodal boundary: ITC ≤0.2 mm and ≤200 cells; micrometastasis >0.2–2 mm and/or >200 cells.

4 · Molecular classification

Pathogenic POLE mutation MMR status p53 status Complete molecular testingNeeded before assigning NSMP.

Add RT Navigator to your Home Screen

Install RT Navigator